It’s Time to Rethink Heart Failure Research

heart failure patient holding hand to heart
By Nancy Newark, R.N., Executive Director, Project Management, Cardiovascular and Metabolic Diseases, Worldwide Clinical Trials,

  Cardiovascular disease remains the number one killer of men and women in the U.S. While the need for new discovery is high, the reality is that little progress has been made to advance treatments during the past few decades – especially for one of the most serious conditions: heart failure.

Read More

What do Cardiovascular Outcome Trials and the Queen Mary have in Common?

Queen Mary
By Chris Standley, Vice President of Vendor Governance, Worldwide Clinical Trials,

On January 12, 2004 when Queen Mary 2 set sail on her maiden voyage from Southampton, England, to Fort Lauderdale, Florida, in the United States, carrying 2,620 passengers, she was both the longest (345 meters – equivalent to 36 London double-decker buses) and largest (148,528 gross tonnage) passenger ship ever built. Whilst she no longer holds these distinctions, she remains the largest ocean liner ever constructed.

Read More

Successfully Mitigating Costs in Large Cardiovascular Outcome Trials

cost mitigation strategies in cardiovascular studies
By Karen Hill, Senior Vice President, Project Management, Cardiometabolic, Worldwide Clinical Trials,

  The rising costs of clinical trials are especially pronounced in large cardiovascular outcome trials (CVOTs) due to the number of patients, investigators, clinical sites, and countries involved. However, there have been several successful attempts by Worldwide Clinical Trials, in partnership with sponsors and others, to mitigate these costs in recent years. Following is a summary of a few cost mitigation strategies employed in CVOTs.

Read More